fda glp-1 warning letters september 2025 News Archives – Partnership for Safe Medicines There's lots going on this

Semaglutide is already established in injectable forms for weight management and diabetes, and this marks its first approval in a high-dose oral format specifically for obesity management

In sepsis, excessive neutrophil activation and NET release shift the endothelium from an anti-inflammatory and anticoagulant phenotype to a pro-inflammatory and pro-coagulant phenotype

That makes it clinically distinct from options like tadalafil or sildenafil, and a better fit for patients whose primary concern is low desire rather than mechanical function

Yes, GLP-1 receptor agonists can reduce appetite and cause nausea, leading to decreased fluid intake and dehydration